-
Ghany MG, Marks KM, Morgan TR, Wyles DL, et al.
Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing,
Managing, and Treating Hepatitis C Virus Infection. Hepatology 2019.
-
Modi S, Saura C, Yamashita T, Park YH, et al.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2019.
-
Cho JH, Lim SH, An HJ, Kim KH, et al.
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR
Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol 2019.
-
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, et al.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant
Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer
Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol 2019.
-
Lee YJ, Okuda Y, Sy J, Lee YK, et al.
Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients
Treated With Reduced-Frequency Hemodialysis. Am J Kidney Dis 2019.
|